Literature DB >> 21135762

Using bevacizumab to treat metastatic cancer: UK consensus guidelines.

D Miles1, J Bridgewater, P Ellis, M Harrison, P Nathan, M Nicolson, S Raouf, D Wheatley, C Plummer.   

Abstract

Concise guidance is lacking for the use of bevacizumab by practicing oncologists. Eight oncologists with experience of bevacizumab were joined by a cardiologist interested in treating hypertension to develop practical guidelines for managing patients receiving bevacizumab, using available clinical data.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21135762     DOI： 10.12968/hmed.2010.71.12.670

Source DB:  PubMed          Journal:  Br J Hosp Med (Lond)        ISSN： 1750-8460            Impact factor:   0.825


  5 in total

1.  Use of bevacizumab as a first-line treatment for metastatic breast cancer.

Authors:  L Manso; F Moreno; R Márquez; B Castelo; A Arcediano; M Arroyo; A I Ballesteros; I Calvo; M J Echarri; S Enrech; A Gómez; R González Del Val; E López-Miranda; M Martín-Angulo; N Martínez-Jañez; C Olier; P Zamora
Journal:  Curr Oncol       Date:  2015-04       Impact factor: 3.677

2.  The efficacy and safety of bevacizumab combined with chemotherapy in treatment of HER2-negative metastatic breast cancer: a meta-analysis based on published phase III trials.

Authors:  Yuan Fang; Xinlan Qu; Boran Cheng; Yuanyuan Chen; Zhenmeng Wang; Fangfang Chen; Bin Xiong
Journal:  Tumour Biol       Date:  2014-11-12

Review 3.  Expert recommendations on the management of hypertension in patients with ovarian and cervical cancer receiving bevacizumab in the UK.

Authors:  Chris Plummer; Agnieszka Michael; Ghazia Shaikh; Michael Stewart; Lynn Buckley; Tracie Miles; Agnes Ograbek; Terry McCormack
Journal:  Br J Cancer       Date:  2019-06-11       Impact factor: 7.640

Review 4.  Targeted anti-vascular therapies for ovarian cancer: current evidence.

Authors:  M Hall; C Gourley; I McNeish; J Ledermann; M Gore; G Jayson; T Perren; G Rustin; S Kaye
Journal:  Br J Cancer       Date:  2013-02-05       Impact factor: 7.640

5.  Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis.

Authors:  Mingyi Zhou; Ping Yu; Xiujuan Qu; Yunpeng Liu; Jingdong Zhang
Journal:  PLoS One       Date:  2013-12-04       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.